

Consolidated balance sheet

in CHF 1 000	Notes	30.06.2025	31.12.2024
Current assets			
Cash and cash equivalents		2 158	458
Securities	3	1 842 495	2 406 881
Other assets		258	60
		1 844 911	2 407 399
Total assets		1 844 911	2 407 399
Current liabilities			
Short-term borrowings from banks	4	–	117 500
Other short-term liabilities		2 315	3 513
Tax liabilities		118	94
		2 433	121 107
Total liabilities		2 433	121 107
Shareholders' equity			
Share capital	5	11 080	11 080
Treasury shares	5	(41 982)	(39 640)
Retained earnings		1 873 380	2 314 852
		1 842 478	2 286 292
Total liabilities and shareholders' equity		1 844 911	2 407 399
Net asset value per share in CHF		33.75	41.75

The notes are an integral part of the condensed consolidated interim financial statements.

The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on July 22, 2025.

Consolidated statement of comprehensive income

in CHF 1 000	Notes	01.01.–30.06.2025	01.01.–30.06.2024	01.04.–30.06.2025	01.04.–30.06.2024
Operating income					
Gains from securities	3	–	192 908	–	–
Interest income		505	32	397	32
Foreign exchange gains		–	–	–	6
Other income		1 279	5	–	–
		1 784	192 945	397	38
Operating expenses					
Losses from securities	3	(321 601)	–	(88 265)	(77 801)
Interest expenses		(55)	(3 005)	–	(1 570)
Foreign exchange losses		(7 301)	(10)	(5 842)	–
Administrative expenses	6	(11 046)	(14 324)	(4 970)	(6 799)
Other expenses		(2 925)	(2 156)	(1 545)	(931)
		(342 928)	(19 495)	(100 622)	(87 101)
Profit/(loss) before tax	7	(341 144)	173 450	(100 225)	(87 063)
Income taxes		(30)	(38)	(15)	(19)
Profit/(loss) for the period		(341 174)	173 412	(100 240)	(87 082)
Total comprehensive profit/(loss) for the period		(341 174)	173 412	(100 240)	(87 082)
Earnings per share in CHF	8	(6.24)	3.16	(1.83)	(1.60)
Diluted earnings per share in CHF	8	(6.24)	3.16	(1.83)	(1.60)

The notes are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of changes in equity

in CHF 1 000	Share capital	Treasury shares	Retained earnings	Total
Balances at January 1, 2024	11 080	(36 508)	2 348 645	2 323 217
Dividend (CHF 2.00 per share)	–	–	(109 692)	(109 692)
Total comprehensive income for the period	–	–	173 412	173 412
Balances at June 30, 2024	11 080	(36 508)	2 412 365	2 386 937
Balances at January 1, 2025	11 080	(39 640)	2 314 852	2 286 292
Dividend (CHF 1.80 per share)	–	–	(98 487)	(98 487)
Trade with treasury shares	–	(2 342)	(1 811)	(4 153)
Total comprehensive income for the period	–	–	(341 174)	(341 174)
Balances at June 30, 2025	11 080	(41 982)	1 873 380	1 842 478

The notes are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of cash flows

in CHF 1 000	Notes	01.01.–30.06.2025	01.01.–30.06.2024
Cash flows from operating activities			
Proceeds from sales of securities	3	483 393	297 341
Purchase of securities	3	(240 608)	(182 219)
Interest receipts		505	32
Other proceeds		1 279	–
Payments for services		(15 370)	(17 096)
Income taxes paid		(4)	(35)
Total cash flows from operating activities		229 195	98 023
Cash flows from financing activities			
Dividend		(98 487)	(109 692)
Proceeds from sales of treasury shares	5	885	–
Purchase of treasury shares	5	(5 037)	–
Proceeds from borrowings	4	–	14 500
Repayment of borrowings	4	(117 500)	–
Interest payments		(55)	(3 005)
Total cash flows from financing activities		(220 194)	(98 197)
Foreign exchange difference		(7 301)	(10)
Change in cash and cash equivalents		1 700	(184)
Cash and cash equivalents at the beginning of the period		458	501
Cash and cash equivalents at the end of the period		2 158	317

The notes are an integral part of the condensed consolidated interim financial statements.

Notes to the consolidated financial statements

1. The Company and its principal activity

BB Biotech AG (the Company) is listed on the SIX Swiss Exchange as well as in the «Prime Standard Segment» of the German Exchange and has its registered office in Schaffhausen, Schwertstrasse 6. Its principal activity is to invest in companies active in the biotechnology industry for the purpose of capital appreciation. The investments are held through its wholly owned subsidiaries.

Company	Capital in CHF 1 000	Capital and voting interest in %
Biotech Focus N.V., Curaçao	11	100
Biotech Growth N.V., Curaçao	11	100
Biotech Invest N.V., Curaçao	11	100
Biotech Target N.V., Curaçao	11	100

2. Accounting policies

The condensed consolidated interim financial statements of the Company and its subsidiary companies (the Group) have been prepared in accordance with International Accounting Standards (IAS) 34 «Interim Financial Reporting», as well as the provisions of the rules of the SIX Swiss Exchange for Investment Companies and should be read in conjunction with the consolidated annual financial statements for the year ended December 31, 2024. The preparation of the condensed consolidated interim financial statements requires management to make assumptions and estimates that have an impact on the balance sheet values and items of the statement of comprehensive income in the current financial period. In certain circumstances, the actual values may diverge from these estimates.

The condensed consolidated interim financial statements have been prepared in accordance with the accounting policies set out in the consolidated annual financial statements.

The following amended standard, valid since January 1, 2025, has been applied in these condensed consolidated interim financial statements:

- IAS 21 (amended, effective January 1, 2025) – Lack of Exchangeability

The following new and amended standards were approved, but will only be applicable for the Group prospectively and were not early adopted in these condensed consolidated interim financial statements:

- IFRS 9/IFRS 7 (amended, effective January 1, 2026) – Classification and Measurement of Financial Instruments
- IFRS 18 (effective January 1, 2027) – Presentation and Disclosure in Financial Statements
- IFRS 19 (effective January 1, 2027) – Subsidiaries without Public Accountability: Disclosures

The Group assessed the potential impact of the above-mentioned new and amended standards. Based on the analysis, the Group concludes that these new and amended standards have no material impact on the Group's accounting policies and overall results and financial position.

The following exchange rates have been used for the preparation of these condensed consolidated interim financial statements:

Currency	30.06.2025	31.12.2024
USD	0.79310	0.90740
XCG ¹⁾	0.44556	0.50978
EUR	0.93482	0.94008
GBP	1.08930	1.13560

¹⁾ since April 1, 2025, Caribbean Guilder, before ANG (Antillean Guilder)

3. Financial assets

Fair Values

The following table presents the Group's assets that are measured at fair value (in CHF 1 000):

30.06.2025	Level 1	Level 2	Level 3	Total
Assets				
Securities				
- Shares	1 799 253	–	43 242	1 842 495
- Derivative instruments	–	–	–	–
Total assets	1 799 253	–	43 242	1 842 495
31.12.2024				
Assets				
Securities				
- Shares	2 369 436	–	37 444	2 406 881
- Derivative instruments	–	–	–	–
Total assets	2 369 436	–	37 444	2 406 881

The table below summarizes the transactions in level 3 instruments (in CHF 1 000):

	01.01.–30.06.2025	01.01.–30.06.2024
Opening balance	37 444	14 725
Purchases	12 079	–
Unrealized gains/(losses) included in gains/losses from securities	(6 281)	1 005
Closing balance	43 242	15 729
Gains/(losses) on level 3 instruments included in gains/losses from securities	(6 281)	1 005

There were no transfers between level 1, 2 and 3 during the reporting period.

The fair value of level 3 instruments at initial recognition represents the transaction price (purchase of preferred stocks of Rivus Pharmaceuticals in August 2022 for TCHF 16 875, August 2024 for TCHF 15 139 and January 2025 for TCHF 12 079), which was paid in financing rounds together with other investors. For the valuation as at June 30, 2025, it is deemed to be appropriate to use the latest transaction price in USD, as it is a reasonable approximation of fair value at the valuation date, based on the information available and in the absence of developments that would reasonably be expected to materially affect fair value.

In August 2022, 8 733 538 Radius Health – Contingent Value Rights were allocated from a corporate action. In February 2025 BB Biotech received USD 1 per Right.

For assets and liabilities carried at amortised cost, their carrying values are a reasonable approximation of fair value.

Securities

The changes in value of securities at fair value through profit or loss by investment category are as follows (in CHF 1 000):

	Listed shares	Unlisted shares	Derivative instruments	Total
Opening balance as at 01.01.2024 at fair values	2 619 989	14 725	–	2 634 714
Purchases	206 303	15 139	316	221 758
Sales	(561 097)	–	(42)	(561 139)
Gains/(losses) from securities	104 241	7 581	(274)	111 548
<i>Realized gains</i>	<i>107 900</i>	–	–	<i>107 900</i>
<i>Realized losses</i>	<i>(46 182)</i>	–	<i>(274)</i>	<i>(46 456)</i>
<i>Unrealized gains</i>	<i>480 172</i>	<i>7 581</i>	–	<i>487 753</i>
<i>Unrealized losses</i>	<i>(437 649)</i>	–	–	<i>(437 649)</i>
Closing balance as at 31.12.2024 at fair values	2 369 436	37 444	–	2 406 881
Opening balance as at 01.01.2025 at fair values	2 369 436	37 444	–	2 406 881
Purchases	228 529	12 079	–	240 608
Sales	(475 493)	–	(7 900)	(483 393)
Gains/(losses) from securities	(323 220)	(6 281)	7 900	(321 601)
<i>Realized gains</i>	<i>117 509</i>	–	<i>7 900</i>	<i>125 409</i>
<i>Realized losses</i>	<i>(51 896)</i>	–	–	<i>(51 896)</i>
<i>Unrealized gains</i>	<i>35 348</i>	–	–	<i>35 348</i>
<i>Unrealized losses</i>	<i>(424 181)</i>	<i>(6 281)</i>	–	<i>(430 462)</i>
Closing balance as at 30.06.2025 at fair values	1 799 253	43 242	–	1 842 495

Securities comprise the following:

Company	Number 31.12.2024	Change	Number 30.06.2025	Market price in original currency 30.06.2025	Valuation CHF mn 30.06.2025	Valuation CHF mn 31.12.2024
Ionis Pharmaceuticals	7 850 000	–	7 850 000	USD	39.51	246.0
Argenx SE	591 000	(31 000)	560 000	USD	551.22	244.8
Neurocrine Biosciences	1 820 000	–	1 820 000	USD	125.69	181.4
Alnylam Pharmaceuticals	760 000	(94 500)	665 500	USD	326.09	172.1
Vertex Pharmaceuticals	475 000	(83 674)	391 326	USD	445.20	138.2
Revolution Medicines	4 374 300	205 000	4 579 300	USD	36.79	133.6
Agios Pharmaceuticals	3 515 150	75 000	3 590 150	USD	33.26	94.7
Incyte	2 150 000	(584 145)	1 565 855	USD	68.10	84.6
Akero Therapeutics	–	1 981 472	1 981 472	USD	53.36	83.9
Scholar Rock Holding	2 486 707	445 000	2 931 707	USD	35.42	82.4
Immunocore	1 205 464	1 236 366	2 441 830	USD	31.38	60.8
Celldex Therapeutics	3 071 615	235 954	3 307 569	USD	20.35	53.4
Beam Therapeutics	1 518 121	1 371 167	2 889 288	USD	17.01	39.0
Biohaven	2 040 853	762 000	2 802 853	USD	14.11	31.4
Blueprint Medicines	–	284 900	284 900	USD	128.18	29.0
Edgewise Therapeutics	1 428 929	1 347 068	2 775 997	USD	13.11	28.9
Moderna	1 600 000	(370 000)	1 230 000	USD	27.59	26.9
Relay Therapeutics	7 375 000	853 578	8 228 578	USD	3.46	22.6
Wave Life Sciences	4 094 458	–	4 094 458	USD	6.50	21.1
Annexon	5 157 290	–	5 157 290	USD	2.40	9.8
Macrogenics	9 929 963	(9 971)	9 919 992	USD	1.21	9.5
Black Diamond Therapeutics	8 517 839	(5 784 292)	2 733 547	USD	2.48	5.4
Intra-Cellular Therapies	2 425 000	(2 425 000)	–	USD	n.a.	–
Arvinas	2 380 000	(2 380 000)	–	USD	7.36	–
Sage Therapeutics	4 460 693	(4 460 693)	–	USD	9.12	–
Esperion Therapeutics	9 944 064	(9 944 064)	–	USD	0.98	–
Fate Therapeutics	4 839 779	(4 839 779)	–	USD	1.12	–
Listed shares					1799.3	2 369.5
Rivus Pharmaceuticals				USD	43.2	37.4
Unlisted shares					43.2	37.4
Total shares					1842.5	2 406.9
Molecular Templates – Warrants, 2.4.29	769 334	–	769 334	USD	0.00	0.0
Radius Health – Contingent Value Right	8 733 538	(8 733 538)	–	USD	0.00	0.0
Total derivative instruments					–	–
Total securities					1842.5	2 406.9

4. Short-term borrowings from banks

At June 30, 2025, there is no short-term loan outstanding (December 31, 2024: CHF 117.5 mn at 0.90% p.a.).

5. Shareholders' equity

The share capital of the Company consists of 55.4 mn fully paid registered shares (December 31, 2024: 55.4 mn) with a par value of CHF 0.20 each (December 31, 2024: CHF 0.20).

Treasury shares

The Company can buy and sell treasury shares in accordance with the Company's articles of association and Swiss company law and in compliance with the listing rules of the SIX Swiss Exchange. During the period from January 1, 2025, to June 30, 2025, the Company has bought 166 750 treasury shares and has sold 30 000 treasury shares (01.01.–30.06.2024: no transactions). As at June 30, 2025, the Company holds 774 750 treasury shares (December 31, 2024: 638 000 shares). The treasury shares as at June 30, 2025, were treated as a deduction from the consolidated shareholders' equity using cost values of TCHF 41 982 (December 31, 2024: TCHF 39 640).

Share buyback 2nd line (bought for cancellation)

The Board of Directors has approved the repurchase of a maximum of 5 540 000 own registered shares with a nominal value of CHF 0.20 each. Until the end of the program at April 11, 2025, 250 750 registered shares were repurchased via a second trading line for the purpose of capital reduction (December 31, 2024: 84 000 shares).

6. Administrative expenses

Administrative expenses comprise the following:

in CHF 1 000	01.01.–30.06.2025	01.01.–30.06.2024
Investment manager		
– Management fees	9 947	13 227
Personnel		
– Board of Directors remuneration	830	835
– Wages and salaries	191	189
– Social insurance contributions and duties	78	73
	11 046	14 324

The remuneration model of BB Biotech AG is determined by the Board of Directors.

Since 2014 the remuneration paid to the investment manager is based upon a 1.1% p.a. all-in fee on the average market capitalization without any additional fixed or performance-based elements of compensation. The compensation of the Board of Directors consists since 2014 of a fixed compensation.

7. Segment reporting

The sole operating segment of the Group reflects the internal management structure and is evaluated on an overall basis. Revenue is derived by investing in a portfolio of companies active in the biotechnology industry for the purpose of capital appreciation. The following results correspond to the sole operating segment of investing in companies active in the biotechnology industry.

The geographical analysis of the profit/(loss) before tax is as follows – all income from financial assets are attributed to a country based on the domiciliation of the issuer of the instrument.

Profit/(loss) before tax in CHF 1 000	01.01.–30.06.2025	01.01.–30.06.2024
Canada	–	(6 505)
Great Britain	(5 147)	(27 408)
Switzerland	(10 103)	(3 158)
Curaçao	(10 714)	(17 098)
Singapore	(24 851)	1 700
British Virgin Islands	(48 358)	(9 557)
Netherlands	(68 731)	48 716
USA	(173 240)	186 761
	(341 144)	173 450

8. Earnings per share

	01.01.–30.06.2025	01.01.–30.06.2024
Total comprehensive profit/(loss) for the period (in CHF 1 000)	(341 174)	173 412
Weighted average number of shares in issue	54 681 464	54 846 000
Earnings per share in CHF	(6.24)	3.16
Income used to determine diluted earnings per share (in CHF 1 000)	(341 174)	173 412
Weighted average number of shares in issue following the dilution	54 681 464	54 846 000
Diluted earnings per share in CHF	(6.24)	3.16

9. Assets pledged

At June 30, 2025, securities in the amount of CHF 1 842.5 mn (December 31, 2024: CHF 2 406.9 mn) are collateral for a credit line of CHF 700 mn (December 31, 2024: CHF 700 mn). At June 30, 2025, there is no short-term loan outstanding (December 31, 2024: CHF 117.5 mn).

10. Transactions with the Investment Manager and related party transactions

Detailed information regarding the remuneration model for the Board of Directors and the investment manager are mentioned under note «6. Administrative Expenses».

11. Commitments, contingencies and other off-balance sheet transactions

The Group had no commitments or other off-balance sheet transactions open at June 30, 2025 and December 31, 2024.

The operations of the Group are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at June 30, 2025, no proceedings existed which could have any material effect on the financial position of the Group (December 31, 2024: none).

12. Subsequent events

There have been no events subsequent to June 30, 2025, which would affect the condensed consolidated interim financial statements.

Report on the review of condensed consolidated interim financial statements

Introduction

We have reviewed the accompanying condensed consolidated balance sheet of BB Biotech AG as of June 30, 2025 and the related condensed consolidated statements of income, changes in equity and cash flows for the six-month period then ended, and a summary of significant accounting policies and other explanatory notes. The Board of Directors is responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 «Interim Financial Reporting» and article 14 of the Directive on Financial Reporting of the SIX Swiss Exchange. Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with the Swiss Auditing Standard 910 (SAS 910) «Engagements to Review Financial Statements» and the International Standard on Review Engagements (ISRE) 2410 «Review of interim financial information performed by the independent auditor of the entity». A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial information for the six months ended June 30, 2025 are not prepared, in all material respects, in accordance with International Accounting Standard 34 Interim Financial Reporting and article 14 of the Directive on Financial Reporting of the SIX Swiss Exchange.

Deloitte AG

Chris Krämer

Licensed Audit Expert
Auditor in Charge

Mathieu Valette

Licensed Audit Expert

Zurich, 22 July 2025

Deloitte AG, Pfingstweidstrasse 11, CH-8005 Zurich
Phone: +41 (0)58 279 60 00, Fax: +41 (0)58 279 66 00, www.deloitte.ch